Ligand Pharmaceuticals Incorporated (LGND : NASDAQ)
Common Stock
$317.33
USD
-1.45 (-0.45%)
Last updated: 2026-10-29
Follow LGND
LGND
Ligand Pharmaceuticals Incorporated
WealthAwesomePerformance
1 Day
-0.45%
1 Week
+3.09%
1 Month
+2.25%
YTD
+20.59%
Key Statistics
Market Cap
$6.36B
52W High
$326.63
52W Low
$175.89
P/E Ratio
33.59
50 Day MA
$295.15
200 Day MA
$251.38
Beta
1.01
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/29/2026 | $315.15 | $323.82 | $309.63 | $317.33 | $317.33 | 299,326 |
| 10/28/2026 | $311.62 | $319.90 | $309.69 | $318.78 | $318.78 | 268,343 |
| 10/27/2026 | $308.51 | $314.19 | $307.55 | $311.73 | $311.73 | 143,400 |
| 10/26/2026 | $304.39 | $309.43 | $303.47 | $308.30 | $308.30 | 194,779 |
| 10/23/2026 | $307.82 | $313.28 | $302.37 | $303.53 | $303.53 | 366,500 |
| 10/22/2026 | $313.00 | $315.27 | $305.34 | $307.82 | $307.82 | 315,129 |
| 10/21/2026 | $305.36 | $317.64 | $303.93 | $314.78 | $314.78 | 222,601 |
| 10/20/2026 | $298.61 | $314.05 | $298.61 | $306.40 | $306.40 | 166,744 |
| 10/19/2026 | $300.41 | $303.86 | $295.74 | $297.28 | $297.28 | 116,989 |
| 10/16/2026 | $297.67 | $297.67 | $292.56 | $295.54 | $295.54 | 164,500 |
Analyst Price Targets
Based on 11 analysts covering LGND · as of Oct 21, 2026
Wall Street analysts forecast LGND stock price to rise 9.0% over the next 12 months.
Consensus
Strong Buy4.73 / 5.00
Avg. Target
US$345.75
+9.0% Upside
Previously US$344.25 on Oct 5, 2026
Current Price
US$317.33
Last close
Analyst Breakdown (11 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LGND's historical volatility
30-Day Vol
33.0%
Annualized
90-Day Vol
30.4%
Annualized
Trend (90d)
+22.5%
Annualized drift
90d Mean
US$343.86
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$325.94 | US$290.89 – US$365.21 |
| 60 trading days | US$334.78 | US$285.03 – US$393.22 |
| 90 trading days | US$343.86 | US$282.36 – US$418.75 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
Financials
- Revenue (TTM)
- $290.54M
- EBITDA
- $133.01M
- Profit Margin
- 67.88%
- ROE (TTM)
- 21.96%
- EPS (Diluted)
- 9.49
- Book Value
- 48.57
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About LGND.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| PCLA | PicoCELA Inc. American Depositary Shares | $11.10 | +86.09% |
| GENVR | Gen Digital Inc. Contingent Value Rights | $1.75 | +65.09% |
| NCPL | Netcapital Inc | $1.78 | +61.82% |
| INLF | INLIF LIMITED Ordinary Shares | $0.27 | +47.22% |
| XCH | XCHG Limited American Depositary Share | $3.46 | +41.80% |
| AMPGZ | Amplitech Group, Inc. Series B Right | $0.05 | +40.80% |
| SGLY | Singularity Future Technology Ltd | $0.50 | +40.17% |
| JFIN | Jiayin Group Inc | $1.72 | +37.60% |
LGND.US news timeline
3 articles covering LGND.US, most recent first
Latest